Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
MAIA Biotechnology, Inc. (NYSE American: MAIA) is Topping The Krypton Street Watchlist This Morning—Wednesday, July 8, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Pull Up MAIA While It’s Still Early… July 8, 2026 Dear Reader, Breaking news just hit this morning and MAIA is the name you need to pull up right now. MAIA Biotechnology, Inc. (NYSE American: MAIA) just reported a 90.5% interim disease control rate from Part C of its Phase 2 THIO-101 expansion trial — in a patient population that was more heavily pre-treated than those in earlier stages of the trial, meaning every patient had previously received docetaxel on top of already being resistant to immunotherapy and other chemotherapies. Standard chemotherapy in this setting delivers a disease control rate of approximately 25 to 35%. MAIA just came in at 90.5%. That is why MAIA is sitting at the very top of the Krypton Street watchlist right now and we are not taking our eyes off it. On June 25, the company announced the completion of international enrollment in Part C of its Phase 2 THIO-101 expansion trial. Domestic enrollment has since expanded to three U.S. clinical sites, including Emory University's NCI-designated Comprehensive Cancer Center. Combined with recent FDA activity, analyst coverage, and leadership share purchases, MAIA has continued building a story that we believe is worth following today. Shares have recently been trending in the $1.50 range, while Noble Capital Markets maintains a $14 target. 
What separates MAIA from the broader small-cap biotech field is the combination of a clinically active Phase 3 pivotal trial, Phase 2 data that meaningfully outperforms the current standard of care, and a regulatory portfolio that reflects FDA recognition of both the science and the unmet medical need behind the program. The Phase 3 THIO-104 trial — the pivotal study positioned to support full commercial approval — began treating patients in December 2025. Within six months, 34 clinical sites had opened across six countries and 29 patients had begun treatment. Noble projects the trial reaching 100 enrolled patients by year-end 2026, creating the potential for an interim overall survival analysis in 2027. Using a Bayesian statistical framework applied to Phase 2 survival data, the firm calculates a 96% probability of success at the interim analysis and 99% at the final analysis. Full pipeline details are available in MAIA’s corporate presentation here. The Phase 2 THIO-101 trial produced a median overall survival of 17.8 months in third-line NSCLC patients — a population where standard chemotherapy typically delivers approximately 5.8 months. The combination also achieved an 88% disease control rate and a 38% overall response rate, both substantially above historical benchmarks for this indication. These are the numbers that informed the Phase 3 design and underpin Noble’s probability-of-success model. According to Benzinga, several members of MAIA's leadership team recently made purchases, complementing a series of recent clinical and regulatory developments. 
About MAIA Biotechnology, Inc. (NYSE American: MAIA) MAIA Biotechnology is a clinical-stage biopharmaceutical company based in Chicago, Illinois. The company is developing ateganosine, also known as THIO, an experimental cancer therapy designed to target telomeres, which play an important role in the way cancer cells continue growing. MAIA’s lead program is focused on third-line non-small cell lung cancer, or NSCLC, a difficult-to-treat patient population that has already received prior immunotherapy and chemotherapy. According to the company, there is currently no FDA-approved standard of care for this group. The company’s active clinical work includes the Phase 2 THIO-101 expansion trial and the Phase 3 THIO-104 pivotal trial. MAIA has also secured clinical supply agreements with BeOne Medicines and Roche for planned or future studies in additional cancer indications. MAIA’s regulatory portfolio includes 3 FDA Orphan Designations, 1 Rare Pediatric Disease Designation, and 1 Fast Track Designation for third-line NSCLC. Its intellectual property portfolio includes 10 issued patents validated across 19 European countries, 36 pending applications, and exclusivity extending into the early 2040s. The leadership team also brings deep oncology and finance experience, led by CEO Vlad Vitoc, MD, MBA, CSO Sergei Gryaznov, PhD, and Head of Finance Jeffrey Himmelreich, MBA. MAIA’s Approach to Checkpoint Therapy
Checkpoint inhibitors have become one of the largest areas in oncology, led by widely used therapies such as Keytruda, Opdivo, and Libtayo. NSCLC remains one of the most important treatment areas in this category. However, the third-line NSCLC setting remains a difficult and underserved segment. These are patients who have already received prior immunotherapy and chemotherapy, and according to MAIA, there is currently no FDA-approved standard of care for this group. That is where MAIA’s approach is focused. Its lead therapy, ateganosine, is designed to be used before a checkpoint inhibitor with the goal of making cancer cells more responsive to immune-based treatment. MAIA is also exploring this approach beyond NSCLC, including planned studies in colorectal cancer, hepatocellular carcinoma, and small cell lung cancer. The company has clinical supply agreements with Regeneron, BeOne Medicines, and Roche, each connected to checkpoint inhibitor combination programs. For readers, the key point is straightforward: MAIA is working in a large oncology category, but its lead focus is a specific patient group where treatment options remain limited. Recent Milestones
- June 25, 2026 — International THIO-101 Part C Enrollment Complete: MAIA completed international patient enrollment in the Phase 2 THIO-101 expansion trial Part C, with domestic enrollment now active at three U.S. sites.
- June 22, 2026 — Noble Capital Markets Reiterates Outperform, $14.00: Analyst Robert LeBoyer published an updated report citing Phase 3 enrollment momentum, new U.S. expansion sites, and a Bayesian probability model placing interim Phase 3 success at 96%.
- June 18, 2026 — Emory Winship Cancer Institute Activated: MAIA opened enrollment at Georgia's only NCI-designated Comprehensive Cancer Center, adding significant institutional credibility to the U.S. THIO-101 expansion footprint.
- June 10, 2026 — Second U.S. THIO-101 Expansion Site Opened: MAIA activated its second domestic clinical site for the THIO-101 Phase 2 international expansion trial, noting that expansion data may support an accelerated FDA approval filing.
- June 4, 2026 — Phase 3 Reports Strong Enrollment and Dosing Momentum: MAIA reported that the THIO-104 Phase 3 pivotal trial had opened 34 sites across six countries and treated 29 patients within six months of first dosing.
- June 3, 2026 — FDA Clears IND for U.S. Phase 2 THIO-101 Enrollment: MAIA received FDA clearance to open U.S. sites in the THIO-101 expansion trial. The updated IND incorporated the latest efficacy data and a refined patient selection strategy.
- June 2, 2026 — CEO and Director Make Open-Market Share Purchases: MAIA's CEO and a board director purchased shares in the open market, signaling internal conviction at current price levels.
- June 1, 2026 — Phase 3 Poster Presented at 2026 ASCO Annual Meeting: MAIA presented a Trial in Progress poster for the THIO-104 Phase 3 pivotal trial at the 2026 American Society of Clinical Oncology annual meeting.
7 Reasons Why MAIA is Topping Our Watchlist This Morning—Wednesday, July 8, 2026…
1. Phase 3 Active: MAIA is already treating patients in its pivotal Phase 3 THIO-104 study, with 34 clinical sites open across six countries within the first six months. 2. Strong Clinical Data: MAIA reported a median overall survival of 17.8 months in its Phase 2 THIO-101 trial, compared with approximately 5.8 months typically seen with standard chemotherapy in this patient population. 3. Recent FDA Progress: MAIA recently completed international enrollment in Part C of its Phase 2 trial while U.S. enrollment continues following FDA clearance earlier this month. 4. Analyst Coverage: MAIA continues to receive coverage from Noble Capital Markets, which reiterated a bullish rating and $14 target in a June 22, 2026 report. 5. Leadership Purchases: According to Benzinga, several members of MAIA's leadership team have recently made open-market share purchases alongside a series of clinical and regulatory updates. 6. Regulatory Recognition: MAIA has received multiple FDA designations, including 3 Orphan Designations, 1 Rare Pediatric Disease Designation, and 1 Fast Track Designation for its lead program. 7. Expanding Pipeline: MAIA is advancing programs beyond NSCLC through clinical supply agreements with Regeneron, BeOne Medicines, and Roche while planning additional studies across multiple cancer indications. Pull Up MAIA While It’s Still Early…
Some companies earn attention because of a single announcement. Others get there by steadily building momentum through a series of meaningful developments. MAIA has done the latter with continued clinical progress, recent FDA activity, encouraging Phase 2 data, an active Phase 3 program, expanding collaborations, and recent leadership share purchases reported by Benzinga. That's why MAIA has landed on the Krypton Street watchlist this morning. We have all eyes on MAIA right now. Take a look at MAIA this morning while it’s still early. Also, keep a look out for my next update—it could be here any moment. Sincerely, Alex Ramsay
Co-Founder & Managing Editor
Krypton Street Newsletter |
